Biognosys’ proprietary P2 Plasma Enrichment System enables plasma proteome profiling with unprecedented depth and throughput, both as contract research and in-house via licensing By offering the ...

MAASTRICHT, Netherlands--(BUSINESS WIRE)--At the International Mass Spectrometry Conference (IMSC 2022), Bruker Corporation (Nasdaq: BRKR) today announced the launch of the new nanoElute® 2 nano-LC, ...

New nanoElute 2 features nano-LC advances, supports automated single cell sample preparation from label-free ProteoCHIP on CellenONE platform MetaboScape® 2023 advances fluxomics applications and ion ...

SCHLIEREN, Switzerland and BILLERICA, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Biognosys AG and Bruker Corporation (Nasdaq: BRKR) today announced a strategic partnership, in which Bruker has made a ...

Tandem Mass Tag™ (TMT™) reagents enable simultaneous identification and relative quantification of thousands of proteins from many samples in a single LC-MS/MS acquisition on Thermo Scientific™ ...

While the vast majority of approved pharmaceuticals target proteins, knowledge of the full complement of proteins that are acted on by drugs, or are potentially druggable, remains incomplete.

Proteomics has become an essential area in medical research, propelled by the ability to quantitatively assess proteins on a large scale using high-throughput technologies. These technologies have ...

Host responses to SARS-CoV-2 are dynamic and complex. Here I will present applications of advanced proteomics technologies to interrogate host responses in the sera, urine and tissue specimens from ...

Proteomics and genomics share the common goal of characterizing biological systems, yet they differ fundamentally in their molecular targets, analytical challenges and interpretive value. Genomics ...

The 21st century has witnessed remarkable advances in molecular biology. Not only are these advances transforming our understanding of life’s most fundamental processes, but they are also starting to ...